Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.
about
Enoxaparin in acute coronary syndromesAnticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Clinical application of enoxaparin.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Low-molecular-weight heparins in the cardiac catheterization laboratoryRole of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Emerging therapies for acute coronary syndromesUS Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
P2860
Q28301431-31D6805D-A5EC-4826-8EA6-78A179DF48EEQ30402038-13F63E5A-AC3C-483C-9866-DB18A555D418Q33360866-EC405795-7FCA-421B-83E0-0E4F80F83BFBQ33360869-75008932-F4EA-4924-BD41-22471BEE6D37Q33685447-B41F3CC3-D3AD-44AD-957A-CC49E1DC4189Q35733959-9EC7C892-8633-429B-9912-8842D515E34CQ35944733-020AB0DB-19B4-46DA-837F-47041B70FD26Q36131116-122701E4-3925-483A-9A62-8BD04A318415Q36164019-69FFB99C-6D48-4D1F-90F6-35B2C777E31BQ37030849-969D8CA4-069D-4F21-8CF5-DC5D75EC8BF9Q37490581-6230A0C4-B025-4D9E-B05D-6E801135E6A6Q37949587-4258EF5C-A037-49ED-868E-3F284E709C2AQ37974873-6781547D-D5B9-49DE-B206-AE36F0B9C4CEQ37978525-195EA420-B281-4E96-AE8C-247C5A24FF22Q40229151-B868DC6C-995D-474C-B388-242EE04AC772
P2860
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Enoxaparin versus tinzaparin i ...... ary syndromes: the EVET trial.
@en
Enoxaparin versus tinzaparin i ...... ary syndromes: the EVET trial.
@nl
type
label
Enoxaparin versus tinzaparin i ...... ary syndromes: the EVET trial.
@en
Enoxaparin versus tinzaparin i ...... ary syndromes: the EVET trial.
@nl
prefLabel
Enoxaparin versus tinzaparin i ...... ary syndromes: the EVET trial.
@en
Enoxaparin versus tinzaparin i ...... ary syndromes: the EVET trial.
@nl
P2093
P1476
Enoxaparin versus tinzaparin i ...... ary syndromes: the EVET trial.
@en
P2093
Christos S Katsouras
Dimitris A Sideris
John Goudevenos
Katerina K Naka
Kostas Adamides
Lampros K Michalis
Nikos Papamichael
P304
P356
10.1016/S0002-8703(03)00179-0
P407
P577
2003-08-01T00:00:00Z